Glucocorticoid-induced osteoporosis.
This article attempts to evaluate the results of several recently published clinical trials of drugs used in the treatment and prevention of glucocorticoid-induced osteoporosis. Despite our lack of understanding regarding the biological mechanisms that lead to glucocorticoid-induced bone loss, effective therapy has been developed. Bisphosphonates have demonstrated significant treatment benefits and should be considered the therapy of choice for both the treatment and prevention of glucocorticoid-induced osteoporosis.
Boulos
P
P
St. Joseph's Hospital, McMaster University, 501 - 25 Charlton Avenue E, Hamilton, Ontario, L8N 1Y2, Canada.
Ioannidis
G
G
Adachi
J D
JD
D002116:Calcitonin / Q000008:administration & dosage; D017610:Calcium Compounds / Q000008:administration & dosage; D004164:Diphosphonates / Q000008:administration & dosage; D005260:Female; D005459:Fluorides / Q000008:administration & dosage; D005938:Glucocorticoids / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D008297:Male; D010024:Osteoporosis / Q000139:chemically induced* / Q000188:drug therapy* / Q000517:prevention & control; D011379:Prognosis; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome; D014807:Vitamin D / Q000008:administration & dosage
D017610:Calcium Compounds; D004164:Diphosphonates; D005938:Glucocorticoids; D014807:Vitamin D; D002116:Calcitonin; D005459:Fluorides